BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010;139:1816-1819. [PMID: 21029802 DOI: 10.1053/j.gastro.2010.10.036] [Cited by in Crossref: 117] [Cited by in F6Publishing: 116] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Bäckhed F, Fraser C, Ringel Y, Sanders M, Sartor R, Sherman P, Versalovic J, Young V, Finlay B. Defining a Healthy Human Gut Microbiome: Current Concepts, Future Directions, and Clinical Applications. Cell Host & Microbe 2012;12:611-22. [DOI: 10.1016/j.chom.2012.10.012] [Cited by in Crossref: 377] [Cited by in F6Publishing: 326] [Article Influence: 37.7] [Reference Citation Analysis]
2 Li X, Lu C, Yang Y, Yu C, Rao Y. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed Pharmacother 2020;129:110486. [PMID: 32768972 DOI: 10.1016/j.biopha.2020.110486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
3 Heimesaat MM, Fischer A, Kühl AA, Göbel UB, Gozes I, Bereswill S. Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice. Eur J Microbiol Immunol (Bp) 2015;5:210-20. [PMID: 26495132 DOI: 10.1556/1886.2015.00025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Liu Z, Cao AT, Cong Y. Microbiota regulation of inflammatory bowel disease and colorectal cancer. Semin Cancer Biol. 2013;23:543-552. [PMID: 24071482 DOI: 10.1016/j.semcancer.2013.09.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
5 Kuchroo VK, Ohashi PS, Sartor RB, Vinuesa CG. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med. 2012;18:42-47. [PMID: 22227671 DOI: 10.1038/nm.2621] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
6 Heimesaat MM, Giladi E, Kühl AA, Bereswill S, Gozes I. The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. Peptides 2018;101:1-9. [PMID: 29288684 DOI: 10.1016/j.peptides.2017.12.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
7 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
8 de Almeida CV, Taddei A, Amedei A. The controversial role of Enterococcus faecalis in colorectal cancer. Therap Adv Gastroenterol 2018;11:1756284818783606. [PMID: 30013618 DOI: 10.1177/1756284818783606] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
9 Bozkurt HS, Kara B. A new treatment for ulcerative colitis: Intracolonic Bifidobacterium and xyloglucan application. Eur J Inflamm 2020;18:205873922094262. [DOI: 10.1177/2058739220942626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Eun CS, Mishima Y, Wohlgemuth S, Liu B, Bower M, Carroll IM, Sartor RB. Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. Infect Immun 2014;82:2239-46. [PMID: 24643531 DOI: 10.1128/IAI.01513-13] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 8.9] [Reference Citation Analysis]
11 Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218-1228. [PMID: 28214091 DOI: 10.1016/s0140-6736(17)30182-4] [Cited by in Crossref: 509] [Cited by in F6Publishing: 265] [Article Influence: 101.8] [Reference Citation Analysis]
12 DuPont HL. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clin Proc. 2015;90:1116-1124. [PMID: 26162610 DOI: 10.1016/j.mayocp.2015.04.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
13 Liu H, Chen F, Wu W, Cao AT, Xue X, Yao S, Evans-Marin HL, Li YQ, Cong Y. TLR5 mediates CD172α(+) intestinal lamina propria dendritic cell induction of Th17 cells. Sci Rep 2016;6:22040. [PMID: 26907705 DOI: 10.1038/srep22040] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
14 Kamguyan K, Torp AM, Christfort JF, Guerra PR, Licht TR, Hagner Nielsen L, Zor K, Boisen A. Colon-Specific Delivery of Bioactive Agents Using Genipin-Cross-Linked Chitosan Coated Microcontainers. ACS Appl Bio Mater 2021;4:752-62. [DOI: 10.1021/acsabm.0c01333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Liaskos C, Spyrou V, Athanasiou LV, Orfanidou T, Mavropoulos A, Rigopoulou EI, Amiridis GS, Shoenfeld Y, Billinis C, Bogdanos DP. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis. Clinics and Research in Hepatology and Gastroenterology 2015;39:384-90. [DOI: 10.1016/j.clinre.2014.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Clark PM, Dawany N, Dampier W, Byers SW, Pestell RG, Tozeren A. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis. 2012;18:2315-2333. [PMID: 22488912 DOI: 10.1002/ibd.22958] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
17 Heimesaat MM, Dunay IR, Alutis M, Fischer A, Möhle L, Göbel UB, Kühl AA, Bereswill S. Nucleotide-oligomerization-domain-2 affects commensal gut microbiota composition and intracerebral immunopathology in acute Toxoplasma gondii induced murine ileitis. PLoS One 2014;9:e105120. [PMID: 25141224 DOI: 10.1371/journal.pone.0105120] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
18 Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res. 2012;159:313-325. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 11.6] [Reference Citation Analysis]
19 Scaldaferri F, Pecere S, Petito V, Zambrano D, Fiore L, Lopetuso LR, Schiavoni E, Bruno G, Gerardi V, Laterza L, Pizzoferrato M, Ianiro G, Stojanovic J, Poscia A, Papa A, Paroni Sterbini F, Sanguinetti M, Masucci L, Cammarota G, Gasbarrini A. Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. Transplant Proc. 2016;48:402-407. [PMID: 27109966 DOI: 10.1016/j.transproceed.2015.12.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
20 Sartor RB, Mazmanian SK. Intestinal Microbes in Inflammatory Bowel Diseases. Am J Gastroenterol Suppl 2012;1:15-21. [DOI: 10.1038/ajgsup.2012.4] [Cited by in Crossref: 142] [Cited by in F6Publishing: 59] [Article Influence: 14.2] [Reference Citation Analysis]
21 Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson's disease: A culprit or a bystander? Prog Brain Res 2020;252:357-450. [PMID: 32247371 DOI: 10.1016/bs.pbr.2020.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
22 Bereswill S, Kühl AA, Alutis M, Fischer A, Möhle L, Struck D, Liesenfeld O, Göbel UB, Dunay IR, Heimesaat MM. The impact of Toll-like-receptor-9 on intestinal microbiota composition and extra-intestinal sequelae in experimental Toxoplasma gondii induced ileitis. Gut Pathog 2014;6:19. [PMID: 24932221 DOI: 10.1186/1757-4749-6-19] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
23 Robertson SJ, Geddes K, Maisonneuve C, Streutker CJ, Philpott DJ. Resilience of the intestinal microbiota following pathogenic bacterial infection is independent of innate immunity mediated by NOD1 or NOD2. Microbes Infect 2016;18:460-71. [PMID: 27083475 DOI: 10.1016/j.micinf.2016.03.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
24 Packey CD, Shanahan MT, Manick S, Bower MA, Ellermann M, Tonkonogy SL, Carroll IM, Sartor RB. Molecular detection of bacterial contamination in gnotobiotic rodent units. Gut Microbes 2013;4:361-70. [PMID: 23887190 DOI: 10.4161/gmic.25824] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
25 Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis 2020;11:456. [PMID: 32541691 DOI: 10.1038/s41419-020-2657-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
26 Zhao J, Nian L, Kwok LY, Sun T, Zhao J. Reduction in fecal microbiota diversity and short-chain fatty acid producers in Methicillin-resistant Staphylococcus aureus infected individuals as revealed by PacBio single molecule, real-time sequencing technology. Eur J Clin Microbiol Infect Dis 2017;36:1463-72. [PMID: 28455781 DOI: 10.1007/s10096-017-2955-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
27 Wang C, Li J. Pathogenic Microorganisms and Pancreatic Cancer. Gastrointest Tumors 2015;2:41-7. [PMID: 26673459 DOI: 10.1159/000380896] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
28 Dieterich W, Schink M, Zopf Y. Microbiota in the Gastrointestinal Tract. Med Sci (Basel) 2018;6:E116. [PMID: 30558253 DOI: 10.3390/medsci6040116] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
29 Kuballa A, Geraci M, Johnston M, Sorrentino D. The Gut Microbial Profile of Preclinical Crohn's Disease Is Similar to That of Healthy Controls. Inflamm Bowel Dis 2020;26:1682-90. [PMID: 32339246 DOI: 10.1093/ibd/izaa072] [Reference Citation Analysis]
30 Baars A, Oosting A, Knol J, Garssen J, van Bergenhenegouwen J. The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5. Microorganisms 2015;3:641-66. [PMID: 27682110 DOI: 10.3390/microorganisms3040641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
31 Shanahan F. The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. Nutr Rev. 2012;70 Suppl 1:S31-S37. [PMID: 22861805 DOI: 10.1111/j.1753-4887.2012.00502.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
32 Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5:7-18. [PMID: 22089028 DOI: 10.1038/mi.2011.55] [Cited by in Crossref: 151] [Cited by in F6Publishing: 157] [Article Influence: 13.7] [Reference Citation Analysis]
33 Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci 2021;21:270-83. [PMID: 33052081 DOI: 10.17305/bjbms.2020.5016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bustos Fernandez LM, Lasa JS, Man F. Intestinal microbiota: its role in digestive diseases. J Clin Gastroenterol. 2014;48:657-666. [PMID: 24921207 DOI: 10.1097/mcg.0000000000000153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
35 Giron F, Pastó A, Tasciotti E, Abraham BP. Nanotechnology in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1871-80. [DOI: 10.1093/ibd/izz205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
36 Jones GR, Fascì-spurio F, Kennedy NA, Plevris N, Jenkinson P, Lyons M, Wong L, Maclean P, Glancy S, Lees CW. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn’s Disease: Correlations Between Disease Activity and Long-Term Follow-Up. Journal of Crohn's and Colitis 2019;13:442-50. [DOI: 10.1093/ecco-jcc/jjy187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Tabbaa OM, Aboelsoud MM, Mattar MC. Long-Term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Center's Experience. Gastroenterology Res 2018;11:397-403. [PMID: 30627262 DOI: 10.14740/gr1091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Buijck M, Berkhout DJ, de Groot EF, Benninga MA, van der Schee MP, Kneepkens CM, de Boer NK, de Meij TG. Sniffing Out Paediatric Gastrointestinal Diseases: The Potential of Volatile Organic Compounds as Biomarkers for Disease. J Pediatr Gastroenterol Nutr 2016;63:585-91. [PMID: 27875502 DOI: 10.1097/MPG.0000000000001250] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
39 Huang YC, Tan XR. Association of gut microbiota with cardiovascular diseases: Present and future. Shijie Huaren Xiaohua Zazhi 2017; 25(1): 31-42 [DOI: 10.11569/wcjd.v25.i1.31] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
40 Mirza AH, Berthelsen CH, Seemann SE, Pan X, Frederiksen KS, Vilien M, Gorodkin J, Pociot F. Transcriptomic landscape of lncRNAs in inflammatory bowel disease. Genome Med. 2015;7:39. [PMID: 25991924 DOI: 10.1186/s13073-015-0162-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 13.9] [Reference Citation Analysis]
41 Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11:1117-1132. [PMID: 25784453 DOI: 10.1016/j.nano.2015.02.018] [Cited by in Crossref: 217] [Cited by in F6Publishing: 188] [Article Influence: 31.0] [Reference Citation Analysis]
42 Ju Z, Chavan SS, Antoine DJ, Dancho M, Tsaava T, Li J, Lu B, Levine YA, Stiegler A, Tamari Y. Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis. PLoS One. 2014;9:e103992. [PMID: 25127031 DOI: 10.1371/journal.pone.0103992] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
43 Joseph SK, Sabitha M, Nair SC. Stimuli-Responsive Polymeric Nanosystem for Colon Specific Drug Delivery. Adv Pharm Bull 2020;10:1-12. [PMID: 32002356 DOI: 10.15171/apb.2020.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
44 Conrad MA, Wu GD, Kelsen JR. The Gut Microbiota and Inflammatory Bowel Disease. In: Mamula P, Grossman AB, Baldassano RN, Kelsen JR, Markowitz JE, editors. Pediatric Inflammatory Bowel Disease. Cham: Springer International Publishing; 2017. pp. 45-54. [DOI: 10.1007/978-3-319-49215-5_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Sharma P, Bhandari C, Kumar S, Sharma B, Bhadwal P, Agnihotri N. Dietary Fibers: A Way to a Healthy Microbiome. Diet, Microbiome and Health. Elsevier; 2018. pp. 299-345. [DOI: 10.1016/b978-0-12-811440-7.00011-9] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
46 Quigley EM. Gut microbiota and the role of probiotics in therapy. Curr Opin Pharmacol. 2011;11:593-603. [PMID: 21996283 DOI: 10.1016/j.coph.2011.09.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
47 Wu W, Song Y, He C, Liu C, Wu R, Fang L, Cong Y, Miao Y, Liu Z. Divalent metal-ion transporter 1 is decreased in intestinal epithelial cells and contributes to the anemia in inflammatory bowel disease. Sci Rep 2015;5:16344. [PMID: 26572590 DOI: 10.1038/srep16344] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
48 Robertson SJ, Goethel A, Girardin SE, Philpott DJ. Innate Immune Influences on the Gut Microbiome: Lessons from Mouse Models. Trends Immunol 2018;39:992-1004. [PMID: 30377046 DOI: 10.1016/j.it.2018.10.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
49 Liu Y, Wang XY. Pulmonary-intestinal crosstalk in the pathological process of COPD and IBD: A perspective from the lung and the large intestine being interior-exteriorly related theory. Shijie Huaren Xiaohua Zazhi 2013; 21(10): 886-893 [DOI: 10.11569/wcjd.v21.i10.886] [Reference Citation Analysis]
50 Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol 2016; 22(42): 9257-9278 [PMID: 27895415 DOI: 10.3748/wjg.v22.i42.9257] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
51 Rogler G, Rosano G. The heart and the gut. European Heart Journal 2014;35:426-30. [DOI: 10.1093/eurheartj/eht271] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
52 Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495-507. [PMID: 25808229 DOI: 10.1007/s00535-015-1064-1] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 17.7] [Reference Citation Analysis]
53 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Eun CS. Intestinal microbiota and inflammatory bowel diseases. J Korean Med Assoc 2021;64:588-95. [DOI: 10.5124/jkma.2021.64.9.588] [Reference Citation Analysis]
55 Underwood MA. Intestinal dysbiosis: novel mechanisms by which gut microbes trigger and prevent disease. Prev Med. 2014;65:133-137. [PMID: 24857830 DOI: 10.1016/j.ypmed.2014.05.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
56 Vedantam G, Viswanathan VK. Unlocking the gates to inflammatory bowel disease: the role of Enterococcus faecalis gelatinase. Gastroenterology 2011;141:795-8. [PMID: 21791208 DOI: 10.1053/j.gastro.2011.07.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Heimesaat MM, Dunay IR, Fuchs D, Trautmann D, Fischer A, Kühl AA, Loddenkemper C, Siegmund B, Batra A, Bereswill S, Liesenfeld O. The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol (Bp) 2011;1:302-10. [PMID: 24516737 DOI: 10.1556/EuJMI.1.2011.4.6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
58 Laubitz D, Harrison CA, Midura-Kiela MT, Ramalingam R, Larmonier CB, Chase JH, Caporaso JG, Besselsen DG, Ghishan FK, Kiela PR. Reduced Epithelial Na+/H+ Exchange Drives Gut Microbial Dysbiosis and Promotes Inflammatory Response in T Cell-Mediated Murine Colitis. PLoS One 2016;11:e0152044. [PMID: 27050757 DOI: 10.1371/journal.pone.0152044] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
59 Bakshi HA, Quinn GA, Aljabali AAA, Hakkim FL, Farzand R, Nasef MM, Abuglela N, Ansari P, Mishra V, Serrano-Aroca Á, Tambuwala MM. Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon. Pharmaceuticals (Basel) 2021;14:1211. [PMID: 34959610 DOI: 10.3390/ph14121211] [Reference Citation Analysis]
60 Guo Y, Zong S, Pu Y, Xu B, Zhang T, Wang B. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease. Molecules 2018;23:E1622. [PMID: 29973488 DOI: 10.3390/molecules23071622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
61 Zhou K, Liu W, Chen Z, Yang D, Qiu Z, Feng H, Li C, Jin M, Li J, Xu Q, Shen Z. The effect of different drinking water in culture medium on feces microbiota diversity. J Water Health 2021;19:267-77. [PMID: 33901023 DOI: 10.2166/wh.2020.075] [Reference Citation Analysis]
62 Heimesaat MM, Grundmann U, Alutis ME, Fischer A, Bereswill S. Microbiota Composition and Immune Responses During Campylobacter Jejuni Infection in Conventionally Colonized IL-10-/- Mice Lacking Nucleotide Oligomerization Domain 2. Eur J Microbiol Immunol (Bp) 2017;7:1-14. [PMID: 28386467 DOI: 10.1556/1886.2016.00038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
63 Nascimento BB, Cartelle CT, Noviello ML, Pinheiro BV, de Almeida Vitor RW, Souza DDG, de Vasconcelos Generoso S, Cardoso VN, Martins FDS, Nicoli JR, Arantes RME. Influence of indigenous microbiota on experimental toxoplasmosis in conventional and germ-free mice. Int J Exp Pathol 2017;98:191-202. [PMID: 28895246 DOI: 10.1111/iep.12236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Wang Y, Miller M, Astrakhan Y, Petersen BS, Schreiber S, Franke A, Bromberg Y. Identifying Crohn's disease signal from variome analysis. Genome Med. 2019;11:59. [PMID: 31564248 DOI: 10.1186/s13073-019-0670-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
65 Sartor RB. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol 2011;4:127-32. [PMID: 21248723 DOI: 10.1038/mi.2010.87] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
66 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 2016;4:30. [PMID: 27338587 DOI: 10.1186/s40168-016-0171-4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 23.3] [Reference Citation Analysis]
67 Thoene-Reineke C, Fischer A, Friese C, Briesemeister D, Göbel UB, Kammertoens T, Bereswill S, Heimesaat MM. Composition of intestinal microbiota in immune-deficient mice kept in three different housing conditions. PLoS One 2014;9:e113406. [PMID: 25401702 DOI: 10.1371/journal.pone.0113406] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
68 Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol 2013;29:85-91. [PMID: 23207600 DOI: 10.1097/MOG.0b013e32835a670e] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
69 Zamani S, Hesam Shariati S, Zali MR, Asadzadeh Aghdaei H, Sarabi Asiabar A, Bokaie S, Nomanpour B, Sechi LA, Feizabadi MM. Detection of enterotoxigenic Bacteroides fragilis in patients with ulcerative colitis. Gut Pathog 2017;9:53. [PMID: 28924454 DOI: 10.1186/s13099-017-0202-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
70 Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62:787-796. [PMID: 23474420 DOI: 10.1136/gutjnl-2012-302504] [Cited by in Crossref: 305] [Cited by in F6Publishing: 260] [Article Influence: 33.9] [Reference Citation Analysis]
71 Buchele V, Konein P, Vogler T, Kunert T, Enderle K, Khan H, Büttner-Herold M, Lehmann CHK, Amon L, Wirtz S, Dudziak D, Neurath MF, Neufert C, Hildner K. Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner. Front Immunol 2020;11:590893. [PMID: 33584655 DOI: 10.3389/fimmu.2020.590893] [Reference Citation Analysis]
72 Xiao M, Shen Z, Luo W, Tan B, Meng X, Wu X, Wu S, Nie K, Tong T, Hong J, Wang X, Wang X. A new colitis therapy strategy via the target colonization of magnetic nanoparticle-internalized Roseburia intestinalis. Biomater Sci 2019;7:4174-85. [PMID: 31380882 DOI: 10.1039/c9bm00980a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Meisel M, Mayassi T, Fehlner-Peach H, Koval JC, O'Brien SL, Hinterleitner R, Lesko K, Kim S, Bouziat R, Chen L, Weber CR, Mazmanian SK, Jabri B, Antonopoulos DA. Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis. ISME J. 2017;11:15-30. [PMID: 27648810 DOI: 10.1038/ismej.2016.114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
74 Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012;56:524-535. [PMID: 22495981 DOI: 10.1002/mnfr.201100630] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 9.1] [Reference Citation Analysis]
75 Park GS, Park MH, Shin W, Zhao C, Sheikh S, Oh SJ, Kim HJ. Emulating Host-Microbiome Ecosystem of Human Gastrointestinal Tract in Vitro. Stem Cell Rev Rep 2017;13:321-34. [PMID: 28488235 DOI: 10.1007/s12015-017-9739-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
76 Sun M, Ban W, Ling H, Yu X, He Z, Jiang Q, Sun J. Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.061] [Reference Citation Analysis]
77 Elinav E, Peer D. Harnessing Nanomedicine for Mucosal Theranostics—A Silver Bullet at Last? ACS Nano 2013;7:2883-90. [DOI: 10.1021/nn400885b] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
78 Liaskos C, Spyrou V, Roggenbuck D, Athanasiou LV, Orfanidou T, Mavropoulos A, Reinhold D, Rigopoulou EI, Amiridis GS, Billinis C, Bogdanos DP. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease. Autoimmunity 2013;46:388-94. [PMID: 23638886 DOI: 10.3109/08916934.2013.786047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
79 Lamousé-Smith ES, Weber S, Rossi RF, Neinstedt LJ, Mosammaparast N, Sandora TJ, McAdam AJ, Bousvaros A. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;57:293-7. [PMID: 23698022 DOI: 10.1097/MPG.0b013e3182999990] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
80 Yoon H, Schaubeck M, Lagkouvardos I, Blesl A, Heinzlmeir S, Hahne H, Clavel T, Panda S, Ludwig C, Kuster B, Manichanh C, Kump P, Haller D, Hörmannsperger G. Increased Pancreatic Protease Activity in Response to Antibiotics Impairs Gut Barrier and Triggers Colitis. Cell Mol Gastroenterol Hepatol 2018;6:370-388.e3. [PMID: 30182050 DOI: 10.1016/j.jcmgh.2018.05.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
81 Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW, Stenson WF, Ciorba MA. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflamm Bowel Dis. 2012;18:1214-1220. [PMID: 21823214 DOI: 10.1002/ibd.21849] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
82 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
83 Doré J, Simrén M, Buttle L, Guarner F. Hot topics in gut microbiota. United European Gastroenterol J. 2013;1:311-318. [PMID: 24917977 DOI: 10.1177/2050640613502477] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
84 Sorrentino D. Microbial dysbiosis in spouses of ulcerative colitis patients: Any clues to disease pathogenesis? World J Gastroenterol 2017; 23(37): 6747-6749 [PMID: 29085220 DOI: 10.3748/wjg.v23.i37.6747] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
85 Moneret-vautrin D. Immunothérapie sublinguale et orale de l’allergie alimentaire : effets cliniques et signification des modifications immunologiques. Revue Française d'Allergologie 2011;51:286-94. [DOI: 10.1016/j.reval.2011.01.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
86 Miner-williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev 2016;29:40-59. [DOI: 10.1017/s0954422416000019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
87 Wang S, Hou Y, Chen W, Wang J, Xie W, Zhang X, Zeng L. KIF9‑AS1, LINC01272 and DIO3OS lncRNAs as novel biomarkers for inflammatory bowel disease. Mol Med Rep 2018;17:2195-202. [PMID: 29207070 DOI: 10.3892/mmr.2017.8118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
88 Maltz RM, Keirsey J, Kim SC, Mackos AR, Gharaibeh RZ, Moore CC, Xu J, Somogyi A, Bailey MT. Social Stress Affects Colonic Inflammation, the Gut Microbiome, and Short-chain Fatty Acid Levels and Receptors. J Pediatr Gastroenterol Nutr 2019;68:533-40. [PMID: 30540706 DOI: 10.1097/MPG.0000000000002226] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
89 Shang H, Sun J, Chen YQ. Clostridium Butyricum CGMCC0313.1 Modulates Lipid Profile, Insulin Resistance and Colon Homeostasis in Obese Mice. PLoS One 2016;11:e0154373. [PMID: 27123997 DOI: 10.1371/journal.pone.0154373] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
90 Nishida A, Lau CW, Zhang M, Andoh A, Shi HN, Mizoguchi E, Mizoguchi A. The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice. Gastroenterology. 2012;142:865-874.e2. [PMID: 22202458 DOI: 10.1053/j.gastro.2011.12.036] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
91 Zeeshan M, Ali H, Khan S, Khan SA, Weigmann B. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. International Journal of Pharmaceutics 2019;558:201-14. [DOI: 10.1016/j.ijpharm.2018.12.074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
92 Ye Y, Zhang L, Hu T, Yin J, Xu L, Pang Z, Chen W. CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn's disease. Sci Rep 2021;11:565. [PMID: 33436852 DOI: 10.1038/s41598-020-80663-w] [Reference Citation Analysis]
93 Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017; 152: 327-339. e4. [PMID: 27769810 DOI: 10.1053/j.gastro.2016.10.012] [Cited by in Crossref: 332] [Cited by in F6Publishing: 309] [Article Influence: 55.3] [Reference Citation Analysis]
94 Chen K, Chen H, Faas MM, de Haan BJ, Li J, Xiao P, Zhang H, Diana J, de Vos P, Sun J. Specific inulin-type fructan fibers protect against autoimmune diabetes by modulating gut immunity, barrier function, and microbiota homeostasis. Mol Nutr Food Res 2017;61. [PMID: 28218451 DOI: 10.1002/mnfr.201601006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
95 Quigley EM. Commensal bacteria: the link between IBS and IBD? Curr Opin Clin Nutr Metab Care. 2011;14:497-503. [PMID: 21673572 DOI: 10.1097/mco.0b013e328348c033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
96 Li X, Fang S, Yu Y, Yang H, Rao Y, Hong D, Lu C, Yu M, Lu X, Yu C, Zhao Q. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chemical Engineering Journal 2022;445:136438. [DOI: 10.1016/j.cej.2022.136438] [Reference Citation Analysis]
97 Bhattarai A, Kowalczyk W, Tran TN. A literature review on large intestinal hyperelastic constitutive modeling. Clin Biomech (Bristol, Avon) 2021;88:105445. [PMID: 34416632 DOI: 10.1016/j.clinbiomech.2021.105445] [Reference Citation Analysis]
98 Raghu Subramanian C, Triadafilopoulos G. Care of inflammatory bowel disease patients in remission. Gastroenterol Rep (Oxf) 2016;4:261-71. [PMID: 27899522 DOI: 10.1093/gastro/gow032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
99 Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol. 2011;19:427-434. [PMID: 21775143 DOI: 10.1016/j.tim.2011.06.005] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 11.9] [Reference Citation Analysis]
100 Sorrentino D. Preclinical and Undiagnosed Crohnʼs Disease: The Submerged Iceberg. Inflammatory Bowel Diseases 2016;22:476-86. [DOI: 10.1097/mib.0000000000000612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
101 Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Digestion. 2017;95:188-193. [PMID: 28288458 DOI: 10.1159/000455008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
102 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
103 Sarabi Asiabar A, Asadzadeh Aghdaei H, Sabokbar A, Zali MR, Feizabadi MM. Investigation of adherent-invasive E. coli in patients with Crohn's disease. Med J Islam Repub Iran 2018;32:11. [PMID: 30159262 DOI: 10.14196/mjiri.32.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Coppens F, Iyyathurai J, Ruer S, Fioravanti A, Taganna J, Vereecke L, De Greve H, Remaut H. Structural and adhesive properties of the long polar fimbriae protein LpfD from adherent-invasive Escherichia coli. Acta Crystallogr D Biol Crystallogr 2015;71:1615-26. [PMID: 26249343 DOI: 10.1107/S1399004715009803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
105 Yang X, Jiang W, Cheng J, Hao J, Han F, Zhang Y, Xu J, Shan C, Wang J, Yang Y, Yang J, Chang B. Reductions in Intestinal Taurine-Conjugated Bile Acids and Short-Chain Fatty Acid-Producing Bacteria Might be Novel Mechanisms of Type 2 Diabetes Mellitus in Otsuka Long-Evans Tokushima Fatty Rats. Exp Clin Endocrinol Diabetes 2021. [PMID: 34929746 DOI: 10.1055/a-1643-1689] [Reference Citation Analysis]
106 Liu P, Gao C, Chen H, Vong CT, Wu X, Tang X, Wang S, Wang Y. Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. Acta Pharm Sin B 2021;11:2798-818. [PMID: 34589398 DOI: 10.1016/j.apsb.2020.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo XS, Lei H, Luk CT, Shi SY, Surendra A, Copeland JK, Ahn J, Prescott D, Rasmussen BA, Chng MH, Engleman EG, Girardin SE, Lam TK, Croitoru K, Dunn S, Philpott DJ, Guttman DS, Woo M, Winer S, Winer DA. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab 2015;21:527-42. [PMID: 25863246 DOI: 10.1016/j.cmet.2015.03.001] [Cited by in Crossref: 170] [Cited by in F6Publishing: 165] [Article Influence: 28.3] [Reference Citation Analysis]
108 Shamriz O, Mizrahi H, Werbner M, Shoenfeld Y, Avni O, Koren O. Microbiota at the crossroads of autoimmunity. Autoimmun Rev 2016;15:859-69. [PMID: 27392501 DOI: 10.1016/j.autrev.2016.07.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 12.2] [Reference Citation Analysis]
109 Hua S. Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors. Front Pharmacol 2020;11:524. [PMID: 32425781 DOI: 10.3389/fphar.2020.00524] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
110 Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10:960-968. [PMID: 22504002 DOI: 10.1016/j.cgh.2012.03.024] [Cited by in Crossref: 85] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
111 Badal VD, Vaccariello ED, Murray ER, Yu KE, Knight R, Jeste DV, Nguyen TT. The Gut Microbiome, Aging, and Longevity: A Systematic Review. Nutrients 2020;12:E3759. [PMID: 33297486 DOI: 10.3390/nu12123759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
112 Sankar SA, Lagier J, Pontarotti P, Raoult D, Fournier P. The human gut microbiome, a taxonomic conundrum. Systematic and Applied Microbiology 2015;38:276-86. [DOI: 10.1016/j.syapm.2015.03.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 10.6] [Reference Citation Analysis]
113 Kotla NG, Rana S, Sivaraman G, Sunnapu O, Vemula PK, Pandit A, Rochev Y. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. Adv Drug Deliv Rev 2019;146:248-66. [PMID: 29966684 DOI: 10.1016/j.addr.2018.06.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
114 Fernández-Tomé S, Ortega Moreno L, Chaparro M, Gisbert JP. Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:10224. [PMID: 34638564 DOI: 10.3390/ijms221910224] [Reference Citation Analysis]
115 Escher U, Giladi E, Dunay IR, Bereswill S, Gozes I, Heimesaat MM. Anti-inflammatory Effects of the Octapeptide NAP in Human Microbiota-Associated Mice Suffering from Subacute Ileitis. Eur J Microbiol Immunol (Bp) 2018;8:34-40. [PMID: 29997909 DOI: 10.1556/1886.2018.00006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
116 Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E. Effect of a Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSan™, on Symptoms, Fatigue and Quality of Life in Patients with Ulcerative Colitis in a Randomized Single-Blinded Placebo Controlled Study. PLoS One 2016;11:e0150191. [PMID: 26933886 DOI: 10.1371/journal.pone.0150191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
117 Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol 2016; 22(7): 2179-2194 [PMID: 26900283 DOI: 10.3748/wjg.v22.i7.2179] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
118 Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:497-508. [PMID: 21692821 DOI: 10.1111/j.1365-2036.2011.04753.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
119 Singhvi N, Gupta V, Gaur M, Sharma V, Puri A, Singh Y, Dubey GP, Lal R. Interplay of Human Gut Microbiome in Health and Wellness. Indian J Microbiol 2020;60:26-36. [PMID: 32089571 DOI: 10.1007/s12088-019-00825-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
120 Cui J, Shi C, Xia P, Ning K, Xiang H, Xie Q. Fermented Deer Blood Ameliorates Intense Exercise-Induced Fatigue via Modulating Small Intestine Microbiota and Metabolites in Mice. Nutrients 2021;13:1543. [PMID: 34063723 DOI: 10.3390/nu13051543] [Reference Citation Analysis]
121 Ye YL, Yin J, Hu T, Zhang LP, Wu LY, Pang Z. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients. World J Gastroenterol 2019; 25(41): 6273-6288 [PMID: 31749597 DOI: 10.3748/wjg.v25.i41.6273] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
122 Huang XZ, Zhu LB, Li ZR, Lin J. Bacterial colonization and intestinal mucosal barrier development. World J Clin Pediatr 2013; 2(4): 46-53 [PMID: 25254174 DOI: 10.5409/wjcp.v2.i4.46] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
123 Shanahan F. The colonic microbiota and colonic disease. Curr Gastroenterol Rep. 2012;14:446-452. [PMID: 22941733 DOI: 10.1007/s11894-012-0281-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]